Update 2021: Management of Small Cell Lung Cancer

Tariq, Sara; Kim, So Yeon; Novaes, Jose Monteiro de Oliveira; Cheng, Haiying

doi:10.1007/s00408-021-00486-y

Cited by 55 publications

(49 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination chemoradiotherapy followed by maintenance immunotherapy is the new standard of care for the upfront management of metastatic SCLC (6). A recent report of IMpower133 (ClinicalTrials.gov identifier: NCT02763579) showed that adding atezolizumab to carboplatin plus etoposide as the first-line treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile in the updated analysis, confirming the regimen as a new standard of care (7).…”

Section: Introductionmentioning

confidence: 93%

“…A recent report of IMpower133 (ClinicalTrials.gov identifier: NCT02763579) showed that adding atezolizumab to carboplatin plus etoposide as the first-line treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile in the updated analysis, confirming the regimen as a new standard of care (7). The standard treatment for LS-SCLS is combined modality treatment, including surgery, radiation, and systemic therapy (6). Surgical resection is recommended for eligible patients with early-stage (I-IIA, T1-2N0) disease who have undergone pathologic mediastinal staging to exclude nodal involvement (6).…”

Section: Introductionmentioning

confidence: 98%

“…The standard treatment for LS-SCLS is combined modality treatment, including surgery, radiation, and systemic therapy (6). Surgical resection is recommended for eligible patients with early-stage (I-IIA, T1-2N0) disease who have undergone pathologic mediastinal staging to exclude nodal involvement (6). For patients with stage IIB to IIIC (T1-T4N0-N3M0) disease, the standard of care is management with concurrent platinum-based chemotherapy and radiotherapy (6).…”

Section: Introductionmentioning

confidence: 99%

“…Surgical resection is recommended for eligible patients with early-stage (I-IIA, T1-2N0) disease who have undergone pathologic mediastinal staging to exclude nodal involvement (6). For patients with stage IIB to IIIC (T1-T4N0-N3M0) disease, the standard of care is management with concurrent platinum-based chemotherapy and radiotherapy (6). Despite these advances in the past several decades, the survival of SCLC has not substantially improved.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis

2022

View full text Add to dashboard Cite

BackgroundPrevious studies have investigated the prognostic value of the systemic immune-inflammation index (SII) in small cell lung cancer (SCLC). However, the results have been inconsistent. The study aimed to investigate the prognostic and clinicopathological significance of SII in SCLC through a meta-analysis.MethodsThe PubMed, Web of Science, Embase, Cochrane Library, and China National Knowledge Infrastructure databases were thoroughly searched. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the prognostic value of the SII for survival outcomes. The combined odds ratios (ORs) and 95% CIs were used to evaluate the correlation between SII and clinicopathological features.ResultsEight studies comprising 2,267 patients were included in the meta-analysis. Pooled analyses indicated that a high SII was significantly associated with worse overall survival (OS) (HR=1.52, 95% CI=1.15–2.00, p=0.003) but not progression-free survival (HR=1.38, 95% CI=0.81–2.35, p=0.238) in patients with SCLC. Moreover, a high SII was associated with extensive-stage SCLC (OR=2.43, 95% CI=1.86–3.17, p<0.001). However, there was a non-significant correlation between SII and age, sex, smoking history, Karnofsky Performance Status score, or initial therapeutic response.ConclusionOur meta-analysis demonstrated that a high SII could be an efficient prognostic indicator of OS in SCLC. We recommend adopting SII to predict OS in patients with SCLC, and SII in combination with other parameters or biomarkers may aid in addressing the clinical strategy and choosing the best treatment for an individual patient.

show abstract

Section: Introductionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis

2022

View full text Add to dashboard Cite

show abstract

“…The field of lung cancer investigation continues to grow and represents a major focus in pulmonary medicine. LUNG participated in the dissemination of evolving knowledge in this area by publishing a State-of-the-Art review on new developments in the diagnosis and management of small-cell lung cancer [ 10 ] in addition to a collection of articles examining lung cancer evaluation, therapy, complications, and survival [ 40 – 48 ].…”

mentioning

confidence: 99%

LUNG Year in Review: 2021

Dicpinigaitis

2022

Lung

View full text Add to dashboard Cite

Immunocytochemical detection by a fully automated immunostainer for assisting subclassification of pulmonary tumors on ThinPrep slides in real‐life clinical samples: A single‐institution experience

Zhao

Sun

et al. 2023

Diagnostic Cytopathology

View full text Add to dashboard Cite

Introduction This study aims to investigate the feasibility and reliability of ThinPrep slides in detecting the subclassification of lung cancer and develop a process for immunocytochemistry (ICC) with optimized staining steps of an automated immunostainer. Methods Cytomorphology and ancillary ICC by automated immunostainer on ThinPrep slides were performed to subclassify 271 cytology cases of pulmonary tumor, which were stained with 2 or more of the following antibodies: p40, p63, thyroid transcription factor‐1 (TTF‐1), Napsin A, synaptophysin (Syn), and CD56. Results The accuracy of cytological subtyping was improved from 67.2% to 92.7% (p < .0001) after ICC. The accuracy of cytomorphology combined with ICC results for lung squamous‐cell carcinoma (LUSC), lung adenocarcinomas (LUAD), and small cell carcinoma (SCLC) was 89.5% (51 of 57), 97.8% (90 of 92), and 98.8% (85 of 86), respectively. The sensitivity and specificity of 6 antibodies were as follows: p63 (91.2%, 90.4%) and p40 (84.2%, 95.1%) for LUSC, TTF‐1(95.6%, 64.6%) and Napsin A (89.7%, 96.7%) for LUAD and Syn (90.7%, 60.0%) and CD56 (97.7%, 50.0%) for SCLC, respectively. P40 expression on ThinPrep slides had the highest agreement (κ = 0.881) with immunohistochemistry (IHC) results, followed by p63 (κ = 0.873), Napsin A (κ = 0.795), TTF‐1 (κ = 0.713), CD56 (κ = 0.576), and Syn (κ = 0.491). Conclusion The result of ancillary ICC on ThinPrep slides by fully automated immunostainer was in good agreement with the gold standard in pulmonary tumors subtype and immunoreactivity, objectively achieving accurate subtyping in cytology.

show abstract

Update 2021: Management of Small Cell Lung Cancer

Cited by 55 publications

References 56 publications

Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis

Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis

LUNG Year in Review: 2021

Immunocytochemical detection by a fully automated immunostainer for assisting subclassification of pulmonary tumors on ThinPrep slides in real‐life clinical samples: A single‐institution experience

Contact Info

Product

Resources

About